3 results about "Scavenger receptor" patented technology

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

The application discloses a monoclonal antibody for identifying human soluble scavenger receptor A, and the amino acid sequences of the heavy chain and the light chain variable region are shown as SEQ ID NO. 1 and SEQ ID NO. 5. A double antibody sandwich detection method is established by using the monoclonal antibody as a capture antibody, the whole operation time is shortened from the conventional 4 hours to 1.5 hours, the detection P / N value is significantly improved, the minimum detection limit reaches 15 pg / mL, and the detectable range is 15-7680 ng / mL. The method is suitable for human soluble scavenger receptor A detection.

Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.